Objective: To explore the effect of brain derived neurotrophic factor (BDNF) transgenic treatment in rats following spinal cord injury (SCI).

Methods: BDNF gene was cloned into plasmid then enveloped with human single herpes virus (HSV) to construct HSV carried BDNF transgenic recombinant. BDNF recombinant was injected into sciatic nerve to last label in motorneurous in the caudal cords, then ventral motor neurons were counted and the area of cell body was measured. The BBB scores representing motor function in hindlimbs was also recorded.

Results: Five days were needed for the GFP-HSV to arrive motorneurons from sciatic nerve. BDNF release could increase the number of motroneurons and inhibit neuronal atrophy in injured spinal cord. BDNF administration also improves motor function in hindlimbs.

Conclusion: BDNF transgene carried by HSV is a useful strategy for the treatment of SCI, indicating its clinic implication in future treatment.

Download full-text PDF

Source

Publication Analysis

Top Keywords

treatment sci
8
hsv carried
8
bdnf
8
carried bdnf
8
bdnf transgene
8
bdnf transgenic
8
spinal cord
8
sciatic nerve
8
motor function
8
[experiment study
4

Similar Publications

Mucinous carcinoma is a rare clinical disease. Although well described in the literature, a mucinous carcinoma diagnosis is often difficult due to its atypical clinical presentation. We report a female patient with a right inguinal mass and ileocecal myxo carcinoma who was misdiagnosed as having a right incarcerated inguinal hernia invading the peritoneum incarcerated inguinal hernia and ileocecal myxo carcinoma.

View Article and Find Full Text PDF

Both irreversible electroporation (IRE) and radiofrequency ablation (RFA) are viable ablation methods for localized treatment of liver tumors. We conducted a meta-analysis to access the efficacy and safety of IRE and RFA in liver cancer treatment. Clinical studies on IRE and RFA for the treatment of liver cancer were collected from PubMed and CNKI until June 2023.

View Article and Find Full Text PDF

Serum symmetric dimethylarginine concentrations in enalapril- or telmisartan-treated dogs with proteinuric chronic kidney disease.

Front Vet Sci

December 2024

Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA, United States.

Introduction: Renin-angiotensin-aldosterone system inhibition (RAASi) reduces intraglomerular pressure and is a standard therapy for dogs with proteinuric chronic kidney disease (CKD). RAASi can acutely decrease glomerular filtration rate (GFR); however, its effects on the marker of GFR serum symmetric dimethylarginine (SDMA) concentration in dogs have not been specifically evaluated. The objective of this study was to evaluate changes, relative to pretreatment values, in serum SDMA concentrations in dogs with proteinuric CKD receiving RAASi therapy.

View Article and Find Full Text PDF

Case report: Clinical and immunohistochemical manifestations of suspected Sjogren's disease in a dog.

Front Vet Sci

November 2024

Department of Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis, Davis, CA, United States.

Sjogren's disease, well-described in people, is rarely identified in veterinary species. In people, Sjogren's disease is one of the most common systemic autoimmune disorders with an incidence of 0.5% in the female population.

View Article and Find Full Text PDF

The aim of this study was to investigate the impact of supplementary feeding with Chinese herbal mixtures on perinatal sows, focusing on their reproductive performance, immunity and breast milk quality. Sixty healthy pregnant sows (Large white, 4 parities) were randomly allocated into five treatment groups ( = 12 per group): the control group received a basal diet, the TRT1 group received a basal diet supplemented with 2 kg/t Bazhen powder (BZP), while the TRT2, TRT3, and TRT4 groups received a basal diet supplemented with 1 kg/t, 2 kg/t, and 3 kg/t Qi-Zhu-Gui-Shao soothing liver and replenishing blood powder (QZGSP), respectively. The trial lasted for a duration of 5 weeks, commencing from day 100 of gestation and concluding on day 21 postpartum.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!